A single-shot mRNA vaccine developed at The University of Texas Medical Branch (UTMB) has shown complete protection against the deadly Andes hantavirus in Syrian hamsters. The research, published by Genetic Engineering News, positions the vaccine as a potential rapid-response tool for future hantavirus outbreaks, which currently lack approved therapies or vaccines.
The study tested the vaccine in a Syrian hamster model, the standard preclinical platform for hantavirus research. All vaccinated animals survived exposure to the Andes hantavirus, the most lethal strain, which causes hantavirus pulmonary syndrome with a case fatality rate of up to 50% in humans. No details on sample size or duration of protection were disclosed.
The mRNA platform mirrors successful COVID-19 vaccine technology but is tailored to target hantavirus surface proteins. UTMB researchers emphasized the vaccine's one-dose regimen as a key advantage for outbreak settings where rapid deployment is critical. The next step involves advancing to clinical trials in humans, though no timeline was provided.
Hantavirus outbreaks are sporadic but devastating, occurring primarily in the Americas. The Andes strain is particularly concerning because it can spread person-to-person, unlike most hantaviruses. A licensed vaccine could fill a glaring gap in pandemic preparedness, though regulatory hurdles and manufacturing scalability remain unaddressed.
While the hamster data is promising, experts caution that animal study results often fail to translate to humans. The lack of published peer-reviewed data and details on immune response durability or safety profiles limits immediate conclusions. If human trials succeed, this could become the first licensed hantavirus vaccine.